This study presents data that provides an understanding of the mechanism of TGF-β1 inhibition by selenium (MSA in vitro and SLM in vivo) and suggests that selenium compounds can be an additional option for the treatment of patients with advanced ccRCC and other cancers expressing selenium targets. Here, TGFB1 is linked to nonpapillary renal cell carcinoma.